# The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea

> **NCT07343635** · NA · RECRUITING · sponsor: **The Fourth Affiliated Hospital of Zhejiang University School of Medicine** · enrollment: 186 (estimated)

## Conditions studied

- Erythematotelangiectatic Rosacea

## Interventions

- **DRUG:** Doxycycline
- **DRUG:** Hydroxychloroquine
- **DRUG:** Tofacitinib
- **DEVICE:** Anti-inflammatory Treatment (Hirudoid Introduction Followed by Yellow Light Therapy)

## Key facts

- **NCT ID:** NCT07343635
- **Lead sponsor:** The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07343635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07343635, "The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07343635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*